Oral Medication Approved for MS in Canada

.

Oral Medication Approved for MS in Canada

Multiple Sclerosis treatment is bound to revolutionize in Canada as drug-maker Novartis Pharmaceutical Canada Inc. announced on Thursday that the first oral medicine for the condition has been approved for use by some patients in the country. The medication will basically help in providing treatment for the symptoms of MS.

The medicine has been named Gilenya and will be available for sale from the 1st of April at pharmaceutical stores across the nation. The medicine will be available for people who have tried another treatment for the condition with poor results.

The chemical name for Gilenya is fingolimod and it will be used for people with the relapsing-remitting form of the condition. According to the figures available, the disease ends up affecting an astounding 75,000 Canadians. People with this variety of the condition are likely to experience new symptoms with severity of older symptoms worsening.

Gilenya will help in reducing flare-ups of people suffering from multiple sclerosis and will also help in reducing the rate of progress. Each capsule of Gilenya contains 0.5 milligrams of the drug and is the most convenient treatment for MS in Canada.

Talking about the development, a Neurologist from Toronto, Dr. Daniel Selchan, said: "The approval of Gilenya is a significant milestone for the Canadian MS community".


Latest News

About 6.4 trillion calories to be cut from food products
Rise in sexually transmitted infections worry all
Breast cancer awareness taken to another level by foundation
Practicing yoga can help bipolar disorder
Oracle’s Chief Larry Ellison Retires
Price of Alibaba IPO Remains at Top Range
Artificial sweeteners might trigger diabetes
World Alzheimer’s Report Suggests Dementia Can Be Preventable
Artificial spleen can rid the body of infections
Obese can lean down through social networking sites: Study
China Plans to Add Stimulus to Boost Economy
Stocks of Sears Drop to 52 Week Low as its CEO Offers Loan of $400 million